AIUM papers highlight CVI-Q progress
Philips Ultrasound is moving forward in its R&D program for Color Velocity Imaging-Quantification(CVI-Q), the vendor's unique non-Doppler method for quantifyingblood volume flow. Ten papers will be presented on CVI and CVI-Qat this week's American
Philips Ultrasound is moving forward in its R&D program for Color Velocity Imaging-Quantification(CVI-Q), the vendor's unique non-Doppler method for quantifyingblood volume flow. Ten papers will be presented on CVI and CVI-Qat this week's American Institute of Ultrasound in Medicine meetingin San Francisco.
Philips spent years developing CVI and CVI-Q and began shippingCVI-Q with its P700 SE scanners in February of 1994. Philips discontinuedthe P700 platform last year, however, in favor of SonoDiagnost800, which it developed in collaboration with Hewlett-Packard(SCAN 12/14/94 and 7/27/94).
Philips made a strategic decision not to ship CVI-Q on theinitial versions of SD 800 in order to position the platform asa mid-range system, according to Joe Balogh, senior marketingmanager for North America. Philips plans to introduce CVI-Q asan upgrade package for SD 800 later this year, he said.
"We decided to introduce the 800 at a mid-range pricepoint," Balogh said. "With CVI and CVI-Q, it would havecome in at a higher price point. We felt we'd gain more exposureestablishing it at the mid-range level."
The papers to be presented at the AIUM meeting cover work donewith the P700, according to Balogh. The papers cover topics rangingfrom the use of CVI-Q to monitor shunts and predict the likelihoodof graft failure to measuring cranial and extremity perfusion.Several presentations indicate that CVI-Q may be superior to conventionalDoppler methods of measuring blood flow.
Where Things Stand with the Radiologist Shortage
June 18th 2025A new report conveys the cumulative impact of ongoing challenges with radiologist residency positions, reimbursement, post-COVID-19 attrition rates and the aging of the population upon the persistent shortage of radiologists in the United States.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
